

# PARTNERING FOR HEALTH

**2013-2014**  
Annual Report



**VIDO-InterVac**

Vaccine and Infectious Disease Organization -  
International Vaccine Centre



UNIVERSITY OF  
SASKATCHEWAN



# TABLE OF CONTENTS

**VIDO-InterVac Vision and Mission** ...2

**Board of Directors** .....2

**Facilitating partnerships for continued success**  
 Message from the Board Chair, John LaClare .....4

**Working together to maximize resources and expertise**  
 Message from the Director and CEO, Andrew Potter .....6

**Vaccine development through partnerships**  
 Volker Gerdt, Associate Director (Research) .....8

**Internal successes facilitate international partnering**  
 Paul D. Hodgson, Associate Director (Business Development) .....13

**New capacity increases research possibilities**  
 Cam Ewart, Associate Director (Operations & Maintenance) .....14

**Harnessing collaboration for innovation**  
 Joyce Sander, Associate Director (Human Resources) .....16

**Investing in partnerships**  
 Lorne Vanin, Associate Director (Finance) .....17

**Statement of Financial Position** .....18

**Statement of Operations** .....18

**Review Statement** .....19

**Community Liaison Committee** .....19

**VIDO-InterVac Contributors** .....Back cover

## OUR VISION

Protecting Canada and the world from infectious diseases

## OUR MISSION

To conduct research and develop vaccines and related products, with key national and international partners, for the prevention and control of human and animal diseases.



**Board of Directors: Back Row (L to R):** Jerome Konecni, Craig Vanderwagen, F. Rainer Engelhardt, Paul Kitching. **Front Row:** Terrance Oleksyn, Andrew Potter, John LaClare, Leonard Edwards, Bill Ballantyne. **Missing:** Luis Barreto, Karen Chad, Robert Clarke, Alastair Cribb, Douglas Freeman

## 2013/2014 VIDO-INTERVAC BOARD OF DIRECTORS

- Bill Ballantyne – Alberta
- Karen Chad – Saskatchewan
- Robert Clarke – Ontario
- Alastair Cribb – Alberta
- Leonard Edwards – Ontario
- Douglas Freeman – Saskatchewan
- Paul Kitching – British Columbia
- Jerome Konecni – Saskatchewan
- John LaClare – Saskatchewan (Chair)
- Terrance Oleksyn – Saskatchewan
- Andrew Potter – Saskatchewan
- Craig Vanderwagen – Maryland, USA
- Luis Barreto (term ended) – Ontario
- F. Rainer Engelhardt (term ended) – Ontario



Ryan Taschuk (Graduate Student)





MESSAGE FROM THE  
**BOARD CHAIR**

## FACILITATING PARTNERSHIPS FOR CONTINUED SUCCESS

Heather Wilson (Scientist)  
and Siew Ng (Research Technician)

**“Partnering for Health” could not be a more appropriate theme for this annual report. It encapsulates the very essence of VIDO-InterVac, the past year’s work and the resulting accomplishments.**

It speaks to the core values of the organization, in particular “collaborative effort.” Fulfilment of the Organization’s Vision and Mission requires scientific excellence, development of internal and external partnerships, infrastructure, management processes, planning, and stakeholder support as well as national and international networks. Partnering for Health is not a singular event, it is an organizational commitment. The very complexity of the disease challenges we are faced with today, and the speed in which they travel the globe demands no less.

**Partnering for Health is not a singular event, it is an organizational commitment**

During the past year the VIDO-InterVac team has continued to build capacity and capability through a number of internal and external initiatives including completion of the strategic plan, advancement of partnerships in Eastern Asia and Africa, ISO 9001 certification and the successful launch of the International Vaccine Centre (InterVac). These accomplishments did not come easily and were the result of a diligent and collaborative effort involving partnerships at multiple levels.

The VIDO-InterVac Board of Directors has, and will continue to be an active participant in the organization. We will work to enhance the organization’s ability to deliver on its mandate through council to the senior management team and by strengthening partnerships at the provincial and federal levels.

The Board of Directors is mindful of the fact that the organization’s progress would not have been possible without collaborative effort and commitment. On behalf of the Board I would like to formally acknowledge the exemplary contribution of Dr. Andrew Potter, the senior management team, the staff, and the partners who contribute to VIDO-InterVac’s success. ♦

*John LaClare*



John LaClare







MESSAGE FROM  
THE **DIRECTOR  
AND CEO**

# WORKING TOGETHER TO MAXIMIZE RESOURCES AND EXPERTISE

Brett Hoffman (Graduate Student)  
and Qiang Liu (Scientist)

Partnership is a common theme in most public and private sector organizations today. From its inception, VIDO-InterVac has relied on regional, national and global partnerships as part of its day to day activities, in part due to our funding model, but as well due to a desire to maximize resources, knowledge and expertise.


The development of sustainable partnerships has been part of our culture since the 1970s and has included traditional scientific collaboration, training, research and development activities with the private sector and numerous other areas.

Given the importance of emerging infectious diseases and the convergence of animal and human health issues, global partnerships are more important today than ever for the mitigation of threats to health and international trade. This is one of the reasons for VIDO-InterVac's expanded activities in the Pacific Rim, Central Asia and Africa. The latter includes work on a number of viral pathogens plus a species of Mycoplasma, all of which are devastating to producers in sub-Saharan Africa and could have significant trade implications should they be detected in other parts of the world. Until recently, we could not effectively work on many emerging infectious diseases since the majority of them required containment level 3 facilities. During the past year, the International Vaccine Centre (InterVac) became fully operational and as envisioned, the facility has supported the research of both internal and external users from the public and private sectors. We anticipate that this will continue into the future with additional international partners making use of the facility.

VIDO-InterVac's mandate includes not only research, but training of highly qualified personnel. Last year we expanded our activities in this area by signing formal agreements with three groups in Guangzhou, China, and have our first trainees at VIDO-InterVac as part of this partnership. We are grateful to the Federal and Provincial governments for the support that they have demonstrated for this initiative, including Minister Lynne Yelich, Minister Rob Norris (SK) and Deputy Minister Alanna Koch to name a few.

Finally, VIDO-InterVac's activities would not be possible without the guidance of our Board of Directors, a group of talented individuals that remain fully engaged in providing oversight and active involvement where appropriate. This has expanded our ability to increase our international activities and ensure Canadian stakeholders' needs are met. ♦

Global partnerships are more important today than ever for the mitigation of threats to health and international trade



Andrew Potter



# VACCINE DEVELOPMENT THROUGH PARTNERSHIPS

BY VOLKER GERDTS **ASSOCIATE DIRECTOR OF RESEARCH**



Gordon Crockford (Research Technician)  
and Claudia Madampage (Post-Doctoral Fellow)

**Infectious diseases continue to affect the health of Canadians and their livestock. Diseases such as measles and pertussis have re-emerged, and have once again become a threat to the health of our children.**

Antimicrobial resistant bacteria such as Methicillin-resistant *Staphylococcus aureus* (MRSA), *Mycobacterium tuberculosis*, and *Neisseria gonorrhoea* are on the rise, and hospital-acquired infections can be found more commonly across the country. Furthermore, new pathogens continue to emerge around the globe with sometimes devastating outcomes for the affected economies and global trade. For example, the Middle Eastern Respiratory Coronavirus (MERS-CoV) was responsible for human deaths and significant concerns remain regarding its host range, the mode of transmission, and the potential for mutating into a more virulent virus that could cause significant disease in humans and animals. The control of infectious diseases through the use of vaccines, therefore, remains a high priority for public health agencies and researchers around the world.

**The control of infectious diseases through the use of vaccines remains a high priority for public health agencies and researchers around the world**

VIDO-InterVac is a world leader in the development of vaccines for both humans and animals. Thanks to the dedication and efforts of our team, we continue to perform cutting-edge research on diseases that are relevant to Canada and the world. Our research is focused on the development of new animal models, host-pathogen interactions, and the development of novel vaccines and vaccine formulations, including adjuvants. Partnerships with academia, government and industry have and will continue to be an important contributor to our success. Indeed, VIDO-InterVac remains a collaborative and welcoming workplace open for partners from around the world. Representing five continents and more than 20 nations, our staff brings a multicultural and interdisciplinary background to our organization. Combined with state-of-the-art infrastructure, including one of the world's

largest biocontainment facilities for animal research, we are well prepared to address present and future infectious disease threats. Examples of our research are given below, and more detail can be found on our website at [www.vido.org](http://www.vido.org).

## **Vaccine development for Porcine Epidemic Diarrhea Virus**

The Porcine Epidemic Diarrhea Virus (PEDV), a coronavirus of pigs, was first diagnosed in the USA in the spring of 2013. Although long known in Asia and Europe, the disease was absent in North America until last year, when the virus infected a herd in the USA. In less than a year the disease spread to over 30 states, killing more than 7 million pigs. With up to 100% mortality in newborn piglets, PEDV is greatly impacting swine producers, their workers and families. In January 2014, the virus was first confirmed in Canada and since then has caused more than 70 outbreaks. Fortunately, due to our well-developed biosecurity measures and the heightened alert of producers and veterinarians involved, all of these outbreaks have been contained. However, the PEDV outbreak demonstrates the susceptibility of our livestock industry to foreign or new infectious disease threats such as foot and mouth disease or African swine fever. Anticipating the spread of PEDV into

*continued next page*



Volker Gerdts



Hollie Lemieux (Animal Health Technician)



Canada, VIDO-InterVac started PEDV vaccine projects in the fall of 2013 to assist our producers in their upcoming battle to control this highly contagious virus. Experimental vaccine candidates are currently being tested in pigs.

### A vaccine for Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and children under two years of age. Following infection, many children experience mild infection of the upper respiratory tract, such as rhinitis, pharyngitis, and/or bronchitis, and subsequently develop an immune response that resolves the infection within days or weeks. In other children, however, RSV can cause severe disease which manifests itself as pneumonia and/or bronchiolitis, often necessitating hospitalization. Furthermore, an increased incidence of asthma has been associated with these more severe lower respiratory tract infections. As there are no vaccines available for this important disease, VIDO-InterVac, in partnership with the Pan-Provincial Vaccine Enterprise (PREVENT) in Canada, the South China United Vaccine Institute, and the Guangzhou Institute of Respiratory Disease developed a novel vaccine candidate found to be highly effective in preclinical trials. Led by Dr. Sylvia van den Hurk, our research team demonstrated vaccine efficacy in mice, cotton rats, and newborn lambs. Importantly, the vaccine was safe and induced long-lasting immunity even in the presence of high levels of maternal antibodies. The RSV vaccine is expected to enter clinical trials in 2015.

With state-of the art infrastructure we are well prepared to address present and future infectious disease threats

### A vaccine for protein misfolding diseases

Protein misfolding diseases, such as Creutzfeldt-Jakob disease, Bovine Spongiform Encephalopathies (BSE), scrapie and chronic wasting disease (CWD), have gained attention over the last decade. Significant trade issues and public health concerns are associated with this group of prion diseases. Chronic wasting disease has devastated the farmed elk industry and the potential for ongoing spread through wild populations, specifically Northern caribou herds, threatens a natural resource of considerable socioeconomic importance. In an effort to provide novel tools for disease management our team, led by Dr. Scott Napper, partnered with University of Toronto and University



**Above:** Brenda Allan (Scientist) and Satender Hansra (Research Technician)

**Right:** Caribou herd in Nunavut 2014 (Naomi Stumborg AREVA Resources Canada Inc.)



of British Columbia researchers to develop an injectable CWD vaccine candidate for farmed deer and elk that targets regions of the protein that are specifically exposed during disease-associated misfolding. The vaccine induces immune responses that are specific for the pathological form of the prion which is significant from both safety and regulatory perspectives. In collaboration with PREVENT, the vaccine is being evaluated for immunogenicity and efficacy in elk studies in our containment level 3 facility. The team is also developing an oral form of the vaccine for immunization of wildlife.

### Vaccines for food security in low-income countries

In partnership with the Kenyan Agriculture Research Institute and the International Livestock Research Institute in Nairobi, we are currently developing a vaccine for Contagious Bovine Pleuropneumonia, one of the most economically important livestock diseases in Africa. The disease, caused by *Mycoplasma mycoides* subspecies *mycoides*, affects approximately 26 low-income countries with an economic impact estimated to exceed 2 billion dollars per year. Traditional methods for disease control and vaccination have not been totally successful. Funded by the International Development Research Centre, the project is aimed at developing an effective and safe vaccine for cattle in Sub-Saharan Africa. Using reverse vaccinology, the team has identified multiple protein targets, which are now being further tested in cattle in Kenya. In addition, Dr. Jose Perez-Casal and his group are also working on a vaccine for *Mycoplasma bovis*, a close relative and important pathogen in the North American beef industry, and are collaborating with the University of Alberta and the United States Department of Agriculture to identify virulence traits in *M. bovis* isolates from bison.


### Improving vaccine efficacy through novel formulations

Killed vaccines require adjuvants that can improve efficacy by enhancing the magnitude of the immune response, extend the duration of immunity, or induce a specific type of immune response. Several adjuvant technologies have been developed at VIDO-InterVac over the years and current research is focused on combining different classes of immune modulators into adjuvant platforms that can be used in combination with a variety of antigens. For example, a combination adjuvant was developed in partnership with several national and international partners that proved highly effective for a number of potential vaccine candidates including pertussis and RSV. This adjuvant is being evaluated in a number of species and for a number of different diseases. For example, our poultry group is investigating the adjuvant's potential for administration into eggs and is developing novel subunit vaccines for infections with *Campylobacter*, *Salmonella* and *Escherichia coli*.

### Novel viral vaccines and viral pathogenesis research

In addition to the diseases described above, VIDO-InterVac is pursuing several vaccines for other viral diseases in pigs. For example, aside from being a human public health concern, swine influenza virus (SIV) infections continue to cause significant production-based losses to the pig industry. Current vaccines for SIV typically use inactivated viruses and require the use of adjuvants and optimal match to the virus causing the disease. As a result, their efficacy is often limited. Led by Dr. Yan Zhou, we have developed a live attenuated influenza vaccine that provides strong, long-lasting immunity to both H1 and H3 SIV subtypes in pigs. Other viral vaccine research is aimed at developing vaccines for Porcine Reproductive and

*continued next page*



Francois Meurens (Scientist)



Respiratory Syndrome Virus (PRRSV), another economically important disease in pigs. In addition to our development of animal vaccines, Dr. Qiang Liu and his group are studying the viral pathogenesis of hepatitis in humans, focusing on both hepatitis B and C virus and their role in disease pathogenesis and liver steatosis.

### Salmonella virulence, transmission and vaccine development

Supported by the Jarislowsky Chair in Biotechnology, Dr. Aaron White and his team are investigating the virulence and transmission of Salmonella, an important human bacterium. Worldwide estimates suggest that Salmonella is responsible for over 50 million cases of human infection and 100,000 deaths each year. It is known that disease-causing Salmonella can survive for long periods of time by forming 'biofilms.' Research at VIDO-InterVac is focused on understanding how these 'biofilms' are related to Salmonella transmission and virulence, and eventually how these can be used for vaccine development. A comparison of 'biofilm'-forming and non 'biofilm'-forming bacteria using next-generation sequencing technology identified more than 500 targets that may block Salmonella 'biofilm' formation and which can potentially be used for the development of a traveler's vaccine against Salmonella food poisoning.

### Vaccines for Sexually Transmitted Diseases

Sexually transmitted diseases continue to be a major health concern worldwide due to their potential to cause infertility and increase the risk for co-infections with human immunodeficiency virus (HIV). In addition, several strains of *Neisseria gonorrhoeae* resistant to all antibiotics have been identified and pose a serious threat to communities where the disease is endemic. Vaccines are not available, and the development of effective vaccines is complicated by the lack of good animal models. In collaboration with Dr. Jo-Anne Dillon and other researchers at VIDO-InterVac, Dr. Francois Meurens and his group are developing a novel animal model for chlamydia and gonorrhea which will enable development and testing of new treatments and vaccine candidates.

### Novel routes of delivery to promote mucosal immunity

The mucosal sites, consisting of the gastrointestinal, respiratory and reproductive tracts, are in constant contact with the external environment such as food, dust particles, and commensal bacteria. The body has evolved to 'ignore' antigens encountered at mucosal sites in order to prevent an inflammatory response to innocuous environmental antigens. However, because an estimated 90% of microorganisms infect humans and animals through mucosal sites, it is extremely beneficial to the host to promote a selective immune response to pathogens encountered there. Dr. Heather Wilson's lab is focused on developing vaccines which are administered to piglets within the first day of life when their gastrointestinal tracts are naturally in a semi-permeable state. The vaccine can cross the gut wall and promote immunity to the vaccine antigens. Her lab is also exploring the impact that administering parvovirus vaccines to gilts/sows during artificial insemination has on promoting protection against parvovirus without negatively affecting fertility.

Numerous advances in pathogenesis research and vaccine development were made over the past year. Our research team, strengthened by our network of partners, continues to develop strategies in an effort to protect humans and animals from infectious disease. ♦

Aaron White (Scientist) and Sumudu Perera (Graduate Student)



## INTERNAL SUCCESSSES FACILITATE INTERNATIONAL PARTNERING

PAUL HODGSON  
ASSOCIATE DIRECTOR  
BUSINESS  
DEVELOPMENT



Paul D. Hodgson

As VIDO-InterVac approaches 40 years of operations we continue to make substantial contributions towards human and animal health.

Over the last year we achieved multiple successes including the completion of three significant milestones, specifically the certification of VIDO-InterVac's management system to ISO 9001 standards; the initiation of containment level 3 experiments in InterVac; and the board's approval of our new 5 year strategic plan. These successes facilitate the ability of our organization to partner internationally.

The ISO certification of our core operational processes and procedures demonstrates to partners that our management system meets internationally certified standards of quality. This external validation and our enhanced focus on quality has already assisted in securing new partnerships worldwide.

The added containment level 3 infrastructure of InterVac provides research capacity not readily available nationally or internationally and further expands opportunities to partner with biotechnology and pharmaceutical companies, livestock producers, and academics to advance infectious disease research and vaccine development to the benefit of the global population. As part of this we have travelled internationally to market VIDO-InterVac and were able to sign several significant agreements including a training and development agreement with China. The signing ceremony in China was attended by the President of Innovation Saskatchewan and the Government of Canada including Minister Lynn Yelich.

Finally, our strategic plan provides a framework to help achieve our revised goals and emphasizes VIDO-InterVac's dedication to helping achieve national priorities in the area of infectious disease research. As evidence of this national commitment we have increased our efforts to align our priorities with agencies of the Government of Canada and revised our vision statement to make specific reference to Canada.

Outbreaks will continue to occur around the world and as a result the social and economic consequences of infectious diseases will not disappear. However, through partnerships and the advancements described above, VIDO-InterVac will help mitigate the threat and impact these diseases will have on human and animal health. ♦

Over the last year we achieved multiple successes including the completion of three significant milestones


Partnership Signing Ceremony:  
Guangzhou, China with  
Minister Lynn Yelich





# NEW CAPACITY INCREASES RESEARCH POSSIBILITIES

CAM EWART **ASSOCIATE DIRECTOR  
OPERATIONS AND MAINTENANCE**



Nathalie Berube (Research Technician)

This past year the focus of operational efforts at VIDO-InterVac has been the initiation of research programs, both within the high containment animal housing suites and the containment level 3 laboratories.

The first Risk Group 3 pathogen was received at the facility in October. Prior to this, a number of research programs using Risk Group 2 pathogens were initiated to familiarize our research teams with the new facilities, its features, and the standard operating procedures. These programs allowed the staff to work in lower risk situations while treating the programs with all the precautions necessary for Risk Group 3 research.

Our annual re-certification process began in the early months of 2014 and required a significant amount of time to test, validate and document the systems within InterVac. The positive relationships established with regulatory agencies during the initial certification remain fundamental as we work to maintain open and clear lines of communication

Our operations team continues to support the research work occurring within VIDO-InterVac. We have added additional team members and have expanded several facility reliability programs.

We take great pride in the end goal of providing uninterrupted operations in our facilities, while ensuring safety for our staff and peace of mind for our surrounding community partners. ♦



Cam Ewart





# HARNESSING COLLABORATION FOR INNOVATION

JOYCE SANDER  
ASSOCIATE DIRECTOR  
HUMAN RESOURCES



Joyce Sander

Our role at the Vaccine and Infectious Disease Organization-International Vaccine Centre is to assist in the maintenance and improvement of human and animal health by protecting Canada and the world from infectious diseases.


We work with federal and provincial governments and agencies, the private sector, non-profit foundations and other organizations to advance infectious disease research through teamwork, collaboration and empowerment.

At VIDO-InterVac we share a common vision and purpose that builds trust and openness. We recognize the value and contribution of all members of our team. This focus on teamwork and equality ensures an actively involved team that is effective, representative, and capable of playing a valued role in the investigation of infectious diseases of humans and animals.

Collaboration is increasingly important as people become more connected around the globe. It not only promotes a happier workforce, it fosters a more educated one. Our collaborative nature helps inspire a sense of community within the organization, making our employees feel like they are part of a family. This strengthens our team by providing employees with the opportunity to learn from each other.

As we expand our partnerships, management strives to empower our employees, which means allowing them more responsibilities and expanding their roles to include leadership. We involve our staff as much as possible in all aspects of decision-making and planning. This involvement increases ownership and commitment and ensures VIDO-InterVac is able to retain our best employees and creates an environment in which people choose to be motivated contributors.

As we continue to advance collaboration and innovation, we will focus on embodying these inspirational words: We will attract the best people, we will develop their skills, we will extend their experience, we will organize them to work together, we will encourage and harness their creativity and we will value them and what they do (John Darley). ♦



Research Team

# INVESTING IN PARTNERSHIPS

LORNE VANIN  
ASSOCIATE DIRECTOR  
FINANCE



Lorne Vanin

Built on a foundation of partnering, VIDO-InterVac continues to achieve success through a strong network of contributors. Our organization receives funding from a wide variety of sources, including federal and provincial governments, producer groups, foundations and industry.


We are accountable to these organizations to ensure their funding is properly managed while being used to advance infectious disease research and vaccine development.

Significant financial activity occurred at VIDO-InterVac during the past year. Revenue increased 20% due in part to large grants awarded from the International Development Research Centre. Although conditional income sources account for the majority of our funding, we will continue to aggressively pursue funding from various government and non-government sources including expanding collaborative research with industry.


Investments in our team, infrastructure, equipment and quality management system ensures VIDO-InterVac remains competitive, continues to generate leading-edge research, and heightens our ability to attract national and international partners. As such, expenses increased 10% over the previous year resulting primarily from expanding activity in our containment level 3 facility and research targeting porcine epidemic diarrhea virus, a new disease in Canada. Controlling expenses and securing sustainable operational funding for our organization remains a high priority.

VIDO-InterVac is grateful to our funders and stakeholders for their continued financial support. The near future will be a very important and interesting time for VIDO-InterVac as containment level 3 operations increase. As always, the finance department will support the management of the organization to help ensure its future success. ♦

## ANNUAL EXPENSE COMPARISON (in millions)



## SOURCES OF REVENUE





	2014	2013
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Funds held - University of Saskatchewan	\$ 17,657,553	\$ 18,963,346
Accounts receivable (Note 3)	6,632,205	7,440,407
Inventories (Note 4)	175,250	107,006
	<b>24,465,009</b>	<b>26,510,759</b>
<b>LONG TERM ASSETS</b>		
Long Term Accounts Receivable (Note 3)	369,896	91,207
Investments	12,184,886	11,583,258
Capital Assets (Note 5)	14,988,105	15,489,481
	<b>\$ 52,007,896</b>	<b>\$ 53,674,706</b>
<b>LIABILITIES</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$ 451,765	\$ 206,696
Accrued vacation pay	735,254	592,418
	<b>1,187,018</b>	<b>799,114</b>
<b>UNEARNED REVENUE</b>	<b>19,468,739</b>	<b>23,164,227</b>
	<b>20,655,757</b>	<b>23,963,341</b>
<b>EQUITY</b>		
INTERNALLY RESTRICTED FUNDS	\$ 14,836,201	\$ 14,221,884
CRITICAL SYSTEMS COMPLIANCE FUND	1,527,833	-
INVESTMENT IN CAPITAL ASSETS	14,988,105	15,489,481
	<b>31,352,139</b>	<b>29,711,365</b>
	<b>\$ 52,007,896</b>	<b>\$ 53,674,706</b>

Unaudited

	2014	2013
<b>INCOME</b>		
Conditional grants	\$ 4,604,602	\$ 2,018,909
Government of Canada	8,239,297	8,037,542
Provincial	926,316	629,533
Other Governments	572,642	1,471,291
Non-Government	757,388	678,061
Commercial contract research	231,649	101,924
Royalties and Licensing Fees	183,498	404,412
Investment income	16,200	16,200
Unconditional revenue	1,230,038	573,442
University of Saskatchewan	15,692	4,500
Miscellaneous Income		1,890
Gain (loss) on disposal of capital assets		
	<b>16,777,322</b>	<b>13,937,703</b>
<b>EXPENDITURE</b>		
Salaries and benefits	7,922,168	7,179,093
Materials and supplies	2,845,684	2,787,682
Maintenance	959,600	629,905
Utilities	990,927	887,068
Sub-contract research	520,768	543,165
Travel and recruiting	487,564	376,169
Patents and legal fees	90,535	103,083
Amortization	1,216,701	1,217,896
Other expenditures	102,601	22,370
	<b>15,136,548</b>	<b>13,746,431</b>
<b>EXCESS OF INCOME OVER EXPENDITURE</b>	<b>1,640,774</b>	<b>191,272</b>
<b>FUND BALANCES, BEGINNING OF YEAR</b>	<b>29,711,365</b>	<b>29,520,093</b>
<b>FUND BALANCES, END OF YEAR</b>	<b>\$ 31,352,139</b>	<b>\$ 29,711,365</b>
<b>INTERNALLY RESTRICTED FUNDS</b>	<b>14,836,201</b>	<b>14,221,884</b>
<b>CRITICAL SYSTEMS COMPLIANCE FUND</b>	<b>1,527,833</b>	<b>-</b>
<b>INVESTMENT IN CAPITAL ASSETS</b>	<b>14,988,105</b>	<b>15,489,481</b>
	<b>\$ 31,352,139</b>	<b>\$ 29,711,365</b>

Unaudited

## COMMUNITY LIAISON COMMITTEE



(L to R): Brian Gibbs, Patricia Roe, Susan Lamb (Chair), Dick Batten, Noreen Jeffrey. **Missing:** Michael Schwandt, Andrew Potter, Dan Paulsen

Susan Lamb

The independent InterVac community liaison committee (CLC) has been meeting since 2007, and is an example of best practices for high containment facilities worldwide.

Made up of community leaders, the role of the CLC is to provide information to the public regarding safety and security at VIDO's containment level 3 laboratory, InterVac, at the University of Saskatchewan. The goal is to create and maintain an atmosphere of public trust and confidence between InterVac and the local and national communities. While the CLC has no authority over the operations of InterVac, the committee has been given the mandate to be informed of InterVac activities when they become of public interest.

Although the committee was active during InterVac's construction years, it has recently refocused with the commissioning of the facility. It meets regularly to be updated by VIDO-InterVac staff on the work being conducted in InterVac. The committee meets annually with the community to provide both a briefing on InterVac and an opportunity for the community to raise any questions or concerns.

## REVIEW STATEMENT

August 27, 2013

The University of Saskatchewan's Financial Reporting Department has examined the Financial Statements as prepared by VIDO and have found that the figures presented therein reconcile to the University's financial records.

In addition, Financial Reporting has reviewed the adjusting transactions and have concluded that the adjustments are reasonable and accurate. Therefore, the University of Saskatchewan can confirm that the statements as presented by VIDO are accurate and in accordance with the University's financial policies.

Financial statement users are cautioned that these statements have not been audited or reviewed for purposes other than those described above.

Dustin Bertsch, CA  
Financial Analyst, Financial Reporting  
Financial Services Division, University of Saskatchewan



# VIDO-INTERVAC CONTRIBUTORS

Advanced Medical Research  
Institute of Canada

Advancing Canadian Agriculture  
and Agri-Food

Agriculture and Agri-Food  
Canada

Agriculture and Food Council  
of Alberta

Alberta Beef Producers

Alberta Chicken Producers

Alberta Food Council

Alberta Innovates-Bio Solutions

Alberta Livestock and Meat  
Agency

Alberta Livestock Industry  
Development Fund

Alberta Milk Production

Alberta Prion Research Institute

Aquila Diagnostic Systems Inc.

Association of Universities and  
Colleges of Canada

Becker-Underwood Inc.

Bill & Melinda Gates Foundation

Beef Cattle Research Council

Beef Farmers of Ontario

Bioniche Life Sciences Inc.

Boehringer Ingelheim  
Vetmedica Inc.

Canada Foundation for  
Innovation

Canadian Institutes of Health  
Research

Canadian Poultry Research  
Council

Canadian Swine Health Board

Cangene Corporation

Cattle Industry Development  
Council

CEVA Sante Animale

Chicken Farmers of  
Saskatchewan

Danone Research

DeNovaMed Inc.

Egg Farmers of Alberta

ELANCO Animal Health

Genome Alberta

Genome BC

Genome Prairie

GlaxoSmithKline Biologicals SA

Government of Canada  
Department of Foreign Affairs  
and International Trade

Government of Canada  
Department of National Defense

Government of Manitoba  
Department of Agriculture, Food  
and Rural Initiatives

Government of Saskatchewan  
Department of Advanced  
Education, Employment and  
Labour

Government of Saskatchewan  
Department of Agriculture and  
Food

Government of Saskatchewan  
Enterprise and Innovation

Health Sciences North

Grand Challenges Canada

International Development  
Research Centre

Jarislowsky Chair in  
Biotechnology Management

Kamloops Stockmen's  
Association

Krembil Foundation

Linnaeus Plant Sciences Inc.

Maple Leaf Foods Inc.

Meadow Ridge Enterprises

Merck Animal Health

Merial Limited

National Pork Board

National Veterinary Research  
and Quarantine Service- Korea

Natural Sciences & Engineering  
Research Council of Canada

Novartis Animal Health

Ontario Ministry of Agriculture  
Food and Rural Affairs

Ontario Pork

Pan-Provincial Vaccine  
Enterprise Inc. (PREVENT)

Pfizer Canada Inc.

Poultry Industry Council

Prevtec Microbia Inc.

PrioNet Canada

Public Health Agency of Canada

Qatar University

Sanofi Pasteur

Saskatchewan BeeKeepers'  
Association

Saskatchewan Chicken Industry  
Investment and Development  
Fund

Saskatchewan Health Research  
Foundation

Saskatchewan Horned Cattle  
Fund

Shastri Indo-Canadian Institute

Synbiotics Corporation

Texas A & M University

University of Alberta

University of British Columbia

University of Calgary

Valorisation-Recherche, S.E.C.

World Health Organization

Zoetis LLC



## VIDO-InterVac

Vaccine and Infectious Disease Organization -  
International Vaccine Centre



## UNIVERSITY OF SASKATCHEWAN